Carl Wild - Concepedia

Author

Carl Wild

Sensei Biotherapeutics (United States)ORCID

Also Known As

C T Wild, C Wild, C. T. Wild, Carl T Wild, Carl T. Wild, Carl Wild, Christopher Wild, Joshi, Pheroze, Wild, Carl

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

Sensei Biotherapeutics (United States)University of North Carolina at Chapel Hill National Cancer Institute Duke University Hospital National Institutes of Health

About

Carl Wild is an author at Sensei Biotherapeutics (United States) specializing in medicine, hiv, and molecular biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	1.8K
2	Natural Sciences	5	5	794
3	Biochemistry	3	3	296
4	Biomolecular Engineering	2	2	506
5	Cell Biology	1	1	20

Carl Wild

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Carl Wild, D C Shugars, Teresa Greenwell, Proceedings of the National Academy of Sciences	1994	932
Capture of an early fusion-active conformation of HIV-1 gp41 Rika A. Furuta, Carl Wild, Yongkai Weng, Nature Structural Biology Protein FoldingHuman RetrovirusAntiviral ResponseMolecular BiologyConformational Study	1998	495
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Carl Wild, Terrence G. Oas, Charlene McDanal, Proceedings of the National Academy of Sciences ImmunologyMolecular BiologySynthetic Peptide InhibitorPeptide SciencePeptide Therapeutics	1992	486
PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing Feng Li, Ritu Goila-Gaur, Karl Salzwedel, Proceedings of the National Academy of Sciences	2003	426
The Ability of an Oligomeric Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Antigen To Elicit Neutralizing Antibodies against Primary HIV-1 Isolates Is Improved following Partial Deletion of the Second Hypervariable Region Susan W. Barnett, Shan Lu, I Srivastava, Journal of Virology ImmunologyViral PathogenesisViral Structural ProteinPrimary Hiv-1 IsolatesPartial Deletion	2001	218
Secretory Leukocyte Protease Inhibitor Binds to Annexin II, a Cofactor for Macrophage HIV-1 Infection Ge Ma, Teresa Greenwell‐Wild, Ke-Jian Lei, The Journal of Experimental Medicine	2004	213
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Carl Wild, J W Dubay, Teresa Greenwell, Proceedings of the National Academy of Sciences Viral ReplicationGlycobiologyImmunologyMolecular BiologyHiv-1 Envelope Oligomerization	1994	200
Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines Derek T. O’Hagan, Manmohan Singh, Mildred Ugozzoli, Journal of Virology	2001	178
Immunogenicity and Protective Efficacy of Oligomeric Human Immunodeficiency Virus Type 1 gp140 Patricia L. Earl, Wataru Sugiura, David C. Montefiori, Journal of Virology	2001	142
In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat) Catherine S. Adamson, Sherimay D. Ablan, Ioana Boeraș, Journal of Virology	2006	124

Page 1